These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Li J; Qin S; Xu R; Yau TC; Ma B; Pan H; Xu J; Bai Y; Chi Y; Wang L; Yeh KH; Bi F; Cheng Y; Le AT; Lin JK; Liu T; Ma D; Kappeler C; Kalmus J; Kim TW; Lancet Oncol; 2015 Jun; 16(6):619-29. PubMed ID: 25981818 [TBL] [Abstract][Full Text] [Related]
6. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Shitara K; Yamanaka T; Denda T; Tsuji Y; Shinozaki K; Komatsu Y; Kobayashi Y; Furuse J; Okuda H; Asayama M; Akiyoshi K; Kagawa Y; Kato T; Oki E; Ando T; Hagiwara Y; Ohashi Y; Yoshino T Ann Oncol; 2019 Feb; 30(2):259-265. PubMed ID: 30508156 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY; Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937 [TBL] [Abstract][Full Text] [Related]
8. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299 [TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. O'Shaughnessy J; DeMichele A; Ma CX; Richards P; Yardley DA; Wright GS; Kalinsky K; Steis R; Diab S; Kennealey G; Geschwindt R; Jiang W; Rugo HS Breast Cancer Res Treat; 2018 Aug; 170(3):547-557. PubMed ID: 29675680 [TBL] [Abstract][Full Text] [Related]
10. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. Hurwitz HI; Uppal N; Wagner SA; Bendell JC; Beck JT; Wade SM; Nemunaitis JJ; Stella PJ; Pipas JM; Wainberg ZA; Manges R; Garrett WM; Hunter DS; Clark J; Leopold L; Sandor V; Levy RS J Clin Oncol; 2015 Dec; 33(34):4039-47. PubMed ID: 26351344 [TBL] [Abstract][Full Text] [Related]
11. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial. Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG; Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Van Den Neste E; André M; Gastinne T; Stamatoullas A; Haioun C; Belhabri A; Reman O; Casasnovas O; Ghesquieres H; Verhoef G; Claessen MJ; Poirel HA; Copin MC; Dubois R; Vandenberghe P; Stoian IA; Cottereau AS; Bailly S; Knoops L; Morschhauser F Haematologica; 2018 May; 103(5):840-848. PubMed ID: 29351986 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846 [TBL] [Abstract][Full Text] [Related]
16. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Van Cutsem E; Yoshino T; Lenz HJ; Lonardi S; Falcone A; Limón ML; Saunders M; Sobrero A; Park YS; Ferreiro R; Hong YS; Tomasek J; Taniguchi H; Ciardiello F; Stoehr J; Oum'Hamed Z; Vlassak S; Studeny M; Argiles G Ann Oncol; 2018 Sep; 29(9):1955-1963. PubMed ID: 30010751 [TBL] [Abstract][Full Text] [Related]
17. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015 [TBL] [Abstract][Full Text] [Related]
18. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946 [TBL] [Abstract][Full Text] [Related]
19. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F; Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911 [TBL] [Abstract][Full Text] [Related]
20. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]